Boston Properties Inc. (BXP) Pops 2.67% for February 10

Equities Staff |

One of the S&P 500’s big winners for Wednesday February 10 was Boston Properties Inc. (BXP) as the company’s stock climbed 2.67% to $111.88 on volume of 439,770 shares.

The stock opened at $109.81 and saw an intraday low of $109.17 and an intraday high of $112.47. All told, the day saw a per-share gain of $2.91. The stock’s average daily volume of 823,632 and 153.58 million shares outstanding. Boston Properties Inc. now has a 50-day SMA is $121.60 and 200-day SMA is $121.21, and it has a 52-week high of $145.90 and a 52-week low of $94.91.

Boston Properties Inc is a fully integrated, self-administered and self-managed real estate investment trust, or REIT, and the owners and developers of office properties in the United States.

Based out of Boston, MA, Boston Properties Inc. has 750 employees and, after today’s trading, reached a market cap of $17.18 billion. The stock’s P/E Ratio is 29.2. Its P/S ratio is 6.72, P/B ratio is 3.04, and P/FCF ratio is -15.6.

For a complete fundamental analysis analysis of Boston Properties Inc., check out’s Stock Valuation Analysis report for BXP. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Veritas Pharma Inc.

Veritas Pharma Inc, formerly Seashore Organic Medicine Inc is an emerging producer and distributor of medical marijuana.

Private Markets


The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…